Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905986 | 1.00 | TSHR (0.44) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL3344866 | 0.92 | ACE (0.51) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL4902997 | 0.92 | ACE (0.51) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL4900062 | 0.89 | MME (0.44) | TSHRMMEACEALDH1A1CCKBR | |
| SCHEMBL5242531 | 0.82 | MME (0.47) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL5242540 | 0.82 | MME (0.47) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL8432066 | 0.81 | ACE (0.63) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL7349910 | 0.81 | ACE (0.63) | TSHRMMEACEALDH1A1L3MBTL1 | |
| SCHEMBL5226142 | 0.80 | KDM1A (0.40) | L3MBTL1KDM1AMAOBKMT2A | |
| SCHEMBL4908073 | 0.79 | TSHR (0.51) | TSHRALDH1A1L3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | BACE1, BACE2, PSEN1 | TSHR 4617/4885MME 312/4885ACE 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.